Reference : Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interact...
Scientific journals : Article
Human health sciences : General & internal medicine
http://hdl.handle.net/2268/103845
Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies.
English
Miossec, P. [> > > >]
Verweij, C. L. [> > > >]
Klareskog, L. [> > > >]
Pitzalis, C. [> > > >]
Barton, A. [> > > >]
Lekkerkerker, F. [> > > >]
Reiter, S. [> >]
Laslop, A. [> > > >]
Breedveld, F. [> > > >]
Abadie, Eric [> > > >]
Flamion, B. [> > > >]
Dere, W. [> > > >]
Mpofu, S. [> > > >]
Goel, N. [> > > >]
Ethgen, Olivier mailto [Université de Liège - ULg > Département des sciences de la santé publique > Santé publique : aspects spécifiques >]
Mitlak, B. [> > > >]
Ormarsdottir, S. [> > > >]
RAO, Rita Flora [Centre Hospitalier Universitaire de Liège - CHU > > Néonatologie non intensive NDB]
Tsouderos, Y. [> > > >]
Reginster, Jean-Yves mailto [Université de Liège - ULg > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé]
2011
Annals of the Rheumatic Diseases
BMJ Group
70
10
1713-8
Yes (verified by ORBi)
International
0003-4967
1468-2060
London
United Kingdom
[en] Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/diagnosis/drug therapy ; Biological Markers/analysis ; Drug Industry ; Drug Monitoring/methods ; Humans ; Individualized Medicine/methods ; Prognosis ; Public-Private Sector Partnerships ; Specimen Handling/methods/standards
[en] Rheumatoid arthritis (RA) is one of the most appropriate conditions for the application of personalised medicine as a high degree of heterogeneity has been recognised, which remains to be explained. Such heterogeneity is also reflected in the large number of treatment targets and options. A growing number of biologics as well as small molecules are already in use and there are promising new drugs in development. In order to make the best use of treatment options, both targeted and non-targeted biomarkers have to be identified and validated. To this aim, new rules are needed for the interaction between academia and industry under regulatory control. Setting up multi-centre biosample collections with clear definition of access, organising early, possibly non-committing discussions with regulatory authorities, and defining a clear route for the validation, qualification and registration of the biomarker-drug combination are some of the more critical areas where effective collaboration between the drug industry, academia and regulators is needed.
http://hdl.handle.net/2268/103845
10.1136/ard.2011.154252

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Biomarkers and personalised medicine in rheumatoid arthritis a proposal for interactions between academia, industry and regulatory bodies.pdfPublisher postprint207.74 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.